Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria
Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care t...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1987 |
|---|
| Umfang: |
3 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Journal of molecular medicine - 1922, 65(1987) vom: Juli, Seite 338-340 |
| Übergeordnetes Werk: |
volume:65 ; year:1987 ; month:07 ; pages:338-340 ; extent:3 |
| Links: |
|---|
| Katalog-ID: |
NLEJ199376379 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ199376379 | ||
| 003 | DE-627 | ||
| 005 | 20230506161757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070527s1987 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ199376379 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria |
| 264 | 1 | |c 1987 | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Wehmeier, A. |4 oth | |
| 700 | 1 | |a Fischer, J. Th. |4 oth | |
| 700 | 1 | |a Goerz, G. |4 oth | |
| 700 | 1 | |a Schneider, W. |4 oth | |
| 773 | 0 | 8 | |i in |t Journal of molecular medicine |d 1922 |g 65(1987) vom: Juli, Seite 338-340 |w (DE-627)NLEJ188988254 |w (DE-600)1462132-0 |x 1432-1440 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:1987 |g month:07 |g pages:338-340 |g extent:3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01745391 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 1987 |c 7 |h 338-340 |g 3 | ||
| matchkey_str |
article:14321440:1987----::oyhmteayfctmeoeosekmanptetihct |
|---|---|
| hierarchy_sort_str |
1987 |
| publishDate |
1987 |
| allfields |
(DE-627)NLEJ199376379 DE-627 ger DE-627 rakwb eng Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered. Springer Online Journal Archives 1860-2002 Wehmeier, A. oth Fischer, J. Th. oth Goerz, G. oth Schneider, W. oth in Journal of molecular medicine 1922 65(1987) vom: Juli, Seite 338-340 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:65 year:1987 month:07 pages:338-340 extent:3 http://dx.doi.org/10.1007/BF01745391 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 65 1987 7 338-340 3 |
| spelling |
(DE-627)NLEJ199376379 DE-627 ger DE-627 rakwb eng Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered. Springer Online Journal Archives 1860-2002 Wehmeier, A. oth Fischer, J. Th. oth Goerz, G. oth Schneider, W. oth in Journal of molecular medicine 1922 65(1987) vom: Juli, Seite 338-340 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:65 year:1987 month:07 pages:338-340 extent:3 http://dx.doi.org/10.1007/BF01745391 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 65 1987 7 338-340 3 |
| allfields_unstemmed |
(DE-627)NLEJ199376379 DE-627 ger DE-627 rakwb eng Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered. Springer Online Journal Archives 1860-2002 Wehmeier, A. oth Fischer, J. Th. oth Goerz, G. oth Schneider, W. oth in Journal of molecular medicine 1922 65(1987) vom: Juli, Seite 338-340 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:65 year:1987 month:07 pages:338-340 extent:3 http://dx.doi.org/10.1007/BF01745391 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 65 1987 7 338-340 3 |
| allfieldsGer |
(DE-627)NLEJ199376379 DE-627 ger DE-627 rakwb eng Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered. Springer Online Journal Archives 1860-2002 Wehmeier, A. oth Fischer, J. Th. oth Goerz, G. oth Schneider, W. oth in Journal of molecular medicine 1922 65(1987) vom: Juli, Seite 338-340 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:65 year:1987 month:07 pages:338-340 extent:3 http://dx.doi.org/10.1007/BF01745391 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 65 1987 7 338-340 3 |
| allfieldsSound |
(DE-627)NLEJ199376379 DE-627 ger DE-627 rakwb eng Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria 1987 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered. Springer Online Journal Archives 1860-2002 Wehmeier, A. oth Fischer, J. Th. oth Goerz, G. oth Schneider, W. oth in Journal of molecular medicine 1922 65(1987) vom: Juli, Seite 338-340 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:65 year:1987 month:07 pages:338-340 extent:3 http://dx.doi.org/10.1007/BF01745391 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 65 1987 7 338-340 3 |
| language |
English |
| source |
in Journal of molecular medicine 65(1987) vom: Juli, Seite 338-340 volume:65 year:1987 month:07 pages:338-340 extent:3 |
| sourceStr |
in Journal of molecular medicine 65(1987) vom: Juli, Seite 338-340 volume:65 year:1987 month:07 pages:338-340 extent:3 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Journal of molecular medicine |
| authorswithroles_txt_mv |
Wehmeier, A. @@oth@@ Fischer, J. Th. @@oth@@ Goerz, G. @@oth@@ Schneider, W. @@oth@@ |
| publishDateDaySort_date |
1987-07-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188988254 |
| id |
NLEJ199376379 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ199376379</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506161757.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1987 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ199376379</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1987</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wehmeier, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fischer, J. Th.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goerz, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schneider, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of molecular medicine</subfield><subfield code="d">1922</subfield><subfield code="g">65(1987) vom: Juli, Seite 338-340</subfield><subfield code="w">(DE-627)NLEJ188988254</subfield><subfield code="w">(DE-600)1462132-0</subfield><subfield code="x">1432-1440</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:65</subfield><subfield code="g">year:1987</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:338-340</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01745391</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">65</subfield><subfield code="j">1987</subfield><subfield code="c">7</subfield><subfield code="h">338-340</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188988254 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-1440 |
| topic_title |
Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a w aw j t f jt jtf g g gg w s ws |
| hierarchy_parent_title |
Journal of molecular medicine |
| hierarchy_parent_id |
NLEJ188988254 |
| hierarchy_top_title |
Journal of molecular medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188988254 (DE-600)1462132-0 |
| title |
Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria |
| spellingShingle |
Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria |
| ctrlnum |
(DE-627)NLEJ199376379 |
| title_full |
Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria |
| journal |
Journal of molecular medicine |
| journalStr |
Journal of molecular medicine |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1987 |
| contenttype_str_mv |
zzz |
| container_start_page |
338 |
| container_volume |
65 |
| physical |
3 |
| format_se |
Elektronische Aufsätze |
| title_sort |
polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria |
| title_auth |
Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria |
| abstract |
Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered. |
| abstractGer |
Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered. |
| abstract_unstemmed |
Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria |
| url |
http://dx.doi.org/10.1007/BF01745391 |
| remote_bool |
true |
| author2 |
Wehmeier, A. Fischer, J. Th Goerz, G. Schneider, W. |
| author2Str |
Wehmeier, A. Fischer, J. Th Goerz, G. Schneider, W. |
| ppnlink |
NLEJ188988254 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| up_date |
2024-07-05T23:54:58.238Z |
| _version_ |
1803785284605706240 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ199376379</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506161757.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1987 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ199376379</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1987</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary The safety of drugs in hepatic porphyrias has largely been established by clinical experience, which is very limited in the case of antineoplastic agents. We administered three cycles of polychemotherapy consisting of daunorubicin, cytarabine and 6-thioguanine, and modified supportive care to a 33-year-old Turkish woman suffering from acute myelogenous leukemia. The urinary excretion of total porphyrins, porphobilinogen, and aminolevulinic acid was continuously monitored. Excreation of these metabolites was permanently elevated, but the values were comparatively low during cytotoxic therapy while peak values were recorded at the onset of fever during bone marrow aplasia; yet there were no clinical signs of porphyritic attacks at that time. A few potentially unsafe drugs were tolerated without an increase in porphyrin excretion. Although the susceptibility to drugs is highly variable in patients with hepatic porphyrias, the treatment of malignancy in these patients seems justified as long as porphyrin excretion under therapy is not grossly elevated over baseline values and appropriately modified supportive care is administered.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wehmeier, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fischer, J. Th.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goerz, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schneider, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of molecular medicine</subfield><subfield code="d">1922</subfield><subfield code="g">65(1987) vom: Juli, Seite 338-340</subfield><subfield code="w">(DE-627)NLEJ188988254</subfield><subfield code="w">(DE-600)1462132-0</subfield><subfield code="x">1432-1440</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:65</subfield><subfield code="g">year:1987</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:338-340</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01745391</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">65</subfield><subfield code="j">1987</subfield><subfield code="c">7</subfield><subfield code="h">338-340</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| score |
7.3972025 |